Investment Rating - The industry investment rating is optimistic [1] Core Insights - The current state of pet hospitals shows a fragmented supply that is awaiting consolidation, while demand is rapidly growing, revealing new opportunities [3][21] - The trend in pet hospitals is moving towards chain development, with a focus on classification integration and specialization [4][50] Summary by Sections 1. Current Development of Pet Hospitals - The supply side of pet hospitals in China is still in the early stages of scale and specialization, with a competitive landscape that is fragmented; the CR3 is only 13% in 2024, and the chain rate is about 25% [3][14] - The pet diagnosis market is expanding quickly, with pet hospitals accounting for nearly 60% of the market; structural opportunities exist, particularly with the increasing number of cats and higher single-consumption rates for dogs [22][31] 2. Development Trends of Pet Hospitals - The chain rate of pet hospitals has steadily increased from 5% in 2017 to 25% in 2024, indicating a fivefold growth [50] - The industry is moving towards a classification and integration model, with 70% of hospitals already offering specialized services, particularly in feline care [55][60]

业绩简评 2025 年 4 月 28 日，公司发布 2024 年年度报告，24 年公司实现收 入 26.78 亿元（同比-1.46%），实现归母净利润-1.02 亿元，扣非 归母净利润-0.85 亿元。 同时公司发布 2025 年一季报，25Q1 公司实现营业收入 7.42 亿元 （同比+9.82%），归母净利润 0.27 亿元（同比+61.18%），扣非归母 净利润 0.28 亿元（同比+48.37%）。 经营分析 屈光术式迭代有望驱动增长，强刚需项目稳健增长。分业务看，屈 光项目 2024 年收入 12.27 亿元（同比下降 5.31%），毛利率 47.02% （同比下降 4.56pct）。公司持续引进蔡司全飞秒精准 4.0 等新技 术，有望进一步巩固竞争优势。白内障项目收入 5.76 亿元（同比 下降 3.04%），受人工晶体国采全面落地及 DRG/DIP 支付改革影响， 呈现"量增价减"态势。24 年白内障项目毛利率 38.93%（同比下 降 4.44pct）。公司通过引进专家、提升服务效率吸引患者，并推 广高端晶体应对集采影响。此外视光项目收入 3.86 亿元，同比下 降 2.60%；综合眼病项目收 ...